Clinical trials · Riverside–San Bernardino, CA
Advanced or Metastatic Solid Tumors clinical trials in Riverside–San Bernardino
We’re tracking 503 recruiting advanced or metastatic solid tumors studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05443126RecruitingPhase 1/Phase 2
Testing a new RET drug for advanced lung cancer
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other tumors with specific genetic changes
This trial tests a new pill, TYRA-430, for people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have certain genetic changes (in the FGF/FGFR pathways). It aims to see if the drug is safe and if it can shrink or slow the growth of the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06028074RecruitingPhase 1/Phase 2
Study of GIM-122 for advanced solid tumors
This trial tests a new drug, GIM-122, in people with advanced solid tumors that have stopped responding to or cannot tolerate standard PD-1/PD-L1 inhibitors. The goal is to see if GIM-122 is safe and tolerable.
Los Angeles, CaliforniaAges 18 years+ - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
Los Angeles, CaliforniaAges 18 years+ - NCT06795022RecruitingPhase 1/Phase 2
Testing AZD9793 for advanced solid tumors with GPC3
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Los Angeles, CaliforniaAges 21 years+ - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Los Angeles, CaliforniaAges 1 month–21 years - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06769698RecruitingPhase 2
Testing fianlimab with cemiplimab for head and neck cancer
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Los Angeles, CaliforniaAges 18–130 - NCT05989828RecruitingPhase 1
Engineered immune cells for advanced triple-negative breast cancer
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT05533697RecruitingPhase 1/Phase 2
mRNA medicine with or without immunotherapy for advanced solid cancers
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Los Angeles, CaliforniaAges 12 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT07282587RecruitingPhase 2
Study of ONC206 for advanced pheochromocytoma and paraganglioma
This trial tests an oral drug called ONC206 (JZP3507) for people with advanced pheochromocytoma or paraganglioma that cannot be removed with surgery. It may be an option if you've already tried standard treatments or cannot take them.
Los Angeles, CaliforniaAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Los Angeles, CaliforniaAges 18 years+ - NCT05832229RecruitingPhase 2
Liver cirrhosis network rosuvastatin trial
This study tests whether the drug rosuvastatin, a cholesterol-lowering medicine, can improve liver health in people with cirrhosis. If you have compensated cirrhosis (no recent serious liver problems), you might be able to join.
Los Angeles, CaliforniaAges 18–75 - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Los Angeles, CaliforniaAges 18 years+ - NCT05836324RecruitingPhase 1
Safety study of an anti-cancer drug for advanced tumors
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- University of California, Los Angeles (UCLA) · 4 studies
- The Angeles Clinic and Research Institute · 3 studies
- USC Norris Comprehensive Cancer Center · 3 studies
- Cedars-Sinai Medical Center · 2 studies
- Research Site · 2 studies
- University of California, Los Angeles · 2 studies
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in California.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 503 recruiting advanced or metastatic solid tumors studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.